Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly | Zendy

Lisa B. Nachtigall | Zendy; Francisco J. Guarda | Zendy; Kate E Lines | Zendy; Alireza Ghajar | Zendy; Laura E. Dichtel | Zendy; Giselle Mumbach | Zendy; Wenxiu Zhao | Zendy; Xun Zhang | Zendy; Nicholas A. Tritos | Zendy; Brooke Swearingen | Zendy; Karen K. Miller | Zendy; Rajesh V. Thakker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly

Author(s) -

Lisa B. Nachtigall,

Francisco J. Guarda,

Kate E Lines,

Alireza Ghajar,

Laura E. Dichtel,

Giselle Mumbach,

Wenxiu Zhao,

Xun Zhang,

Nicholas A. Tritos,

Brooke Swearingen,

Karen K. Miller,

Rajesh V. Thakker

Publication year - 2020

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgaa142

Subject(s) - acromegaly , medicine , men1 , genetic testing , context (archaeology) , multiple endocrine neoplasia , primary hyperparathyroidism , cohort , gastroenterology , endocrine system , genetics , gene , hormone , biology , growth hormone , paleontology

Clinical multiple endocrine neoplasia type 1 (MEN-1) is diagnosed by the presence of at least 2 MEN-1-associated tumors. Many patients with acromegaly and clinical MEN-1 yield negative testing for MEN1 mutations. While cases of acromegaly and primary hyperparathyroidism (PHP) with negative genetic testing have been reported, its prevalence among patients with acromegaly is undetermined, and the clinical presentation has not been well characterized.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research